In an unusual step, the Food and Drug Administration withdrew a draft guidance that was issued last fall to help companies develop biosimilar medicines that resemble brand-name biologics.
By doing so, the agency acquiesced to concerns expressed in recent months by companies over some of the recommendations that were made for concocting a biosimilar, which is a nearly identical variant of a biologic medicine and is expected to provide the same result in patients.
About the Author Reprints
